Clinical Trial for Prostate Cancer
This study has been completed.
Sponsor:
Oakwood Laboratories, LLC
Information provided by:
Oakwood Laboratories, LLC
ClinicalTrials.gov Identifier:
NCT00076531
First received: January 26, 2004
Last updated: January 24, 2008
Last verified: January 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Phase III trial using an injectable for treatment of prostate cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Prostate Cancer |
Drug: Leuprolide Acetate for Injectable Suspension 22.5 mg |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Masking: Open Label Primary Purpose: Treatment |
Resource links provided by NLM:
Further study details as provided by Oakwood Laboratories, LLC:
Eligibility| Ages Eligible for Study: | 40 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Contacts and Locations More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00076531 History of Changes |
| Other Study ID Numbers: | OL-007 |
| Study First Received: | January 26, 2004 |
| Last Updated: | January 24, 2008 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Oakwood Laboratories, LLC:
|
Prostate Cancer PSA Leuprolide |
Additional relevant MeSH terms:
|
Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Leuprolide |
Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Fertility Agents, Female Fertility Agents Reproductive Control Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on May 21, 2013